home About Us People Portfolio News Contact Us Fund I Investor Login » Fund II Investor Login » Fund III Investor Login »


Jan22Nathan Hukill Joins Capital Royalty as Managing Director

Houston, TX - January 22, 2009 – Capital Royalty L.P. (“Capital Royalty”) announced today that Nathan D. Hukill, a recognized pioneer in royalty bond financing, has joined the firm as a Managing Director effective (date).  In conjunction with his appointment, Mr. Hukill will oversee the opening and management of Capital Royalty’s new office in Boulder, Colorado in an effort to better source and serve Western biopharmaceutical hubs.


Mr. Hukill brings over a decade of investing and structuring experience to Capital Royalty, most recently as a Portfolio Manager at Highland Capital Management, L.P, a registered investment advisor with over $20 billion of assets under management, where he invested and managed approximately $4.5 billion in alternative assets focused primarily on healthcare investments. Mr. Hukill spearheaded Highland Capital’s entry into biopharmaceutical royalties, becoming the largest buyer of biopharmaceutical royalty bonds in the industry. 


Over the course of his career, Mr. Hukill served on the board of directors at Epocal, Inc. a blood diagnostics company; Complete Genomics, Inc., a genomics sequencing company; and, Solstice Neurosciences, a biotechnology company. Additionally he was a co-founder and CFO of OpenQ, a pharmaceutical software company.


“Our stated goal is to strengthen and position Capital Royalty for market leadership in healthcare investing for the future. Our plan is three-fold:  assemble a world-class investment team that unites the finest pioneers and innovators in healthcare financing; sharpen our collective vision to enhance our competitive market advantage; and, refine our royalty investment strategy to attract the highest-quality IP assets through the design of innovative royalty financing structures,” said Charles W. Tate, Capital Royalty Founder and Chairman.


“Nate clearly represents one of our industry’s foremost market pioneers in royalty bond financing.  His distinguished career, established reputation and successful track record significantly enhance and complement Capital Royalty’s strengths in traditional royalty financing. We are excited to have Nate join our leadership team,” said Mr. Tate.  


With the addition of Mr. Hukill, Capital Royalty also announced the opening of its Boulder, Colorado office. “The opening of our Boulder office is designed to enhance Capital Royalty’s national market presence and better source and serve our partner relationships. The Boulder office will provide broader coverage of our Western markets, particularly the biotech hubs in San Francisco, San Diego and Boulder/Denver,” Mr. Tate concluded.



Founded in 2003, Capital Royalty L.P. is a market pioneer and innovator in healthcare investing with a focus on intellectual property investments in FDA-approved biopharmaceutical assets through royalty bond and other royalty monetization structures. Collectively, the Capital Royalty investment team has more than 140 years of healthcare, capital markets, private equity and investment banking experience, having completed more than 50 royalty transactions representing $3.7 billion in capital over the past fifteen years. Capital Royalty focuses on sourcing, structuring and investing in healthcare royalty monetization transactions that target attractive risk-adjusted returns with superior downside protection for investors.  The Firm is headquartered in Houston, Texas with an office in Boulder, Colorado. For further information, please visit www.capitalroyalty.com